Gene expression profiles associated with inflammation, fibrosis, and cholestasis in mouse liver after Griseofulvin

Environmental Health Perspectives

Volumn 111, Issue 1 T, 2003, Pages 37-44

  Gant, Timothy W ^a   Baus, Petra R ^a   Clothier, Bruce ^a   Riley, Joan ^a   Davies, Reginald ^a   Judah, David J ^a   Edwards, Richard E ^a   George, Elisabeth ^b   Greaves, Peter ^a   Smith, Andrew G ^a  

^a UNIVERSITY OF LEICESTER   (United Kingdom)

^b GLAXOSMITHKLINE   (United Kingdom)

Author keywords

Fibrosis; Inflammation; Liver; Microarray; Protoporphyria

Indexed keywords

BILE ACID; CALCYCLINE; CELL PROTEIN; CYTOCHROME P450 2A; CYTOCHROME P450 2B; CYTOCHROME P450 3A; CYTOCHROME P450 4A; GRISEOFULVIN; STEROID; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; CELL PROLIFERATION; CLINICAL CHEMISTRY; CONTROLLED STUDY; DISEASE ASSOCIATION; DNA DAMAGE; DRUG RESPONSE; ERYTHROPOIETIC PROTOPORPHYRIA; FIBROBLAST; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENETIC TRANSCRIPTION; HOMEOSTASIS; INFLAMMATION; INTRAHEPATIC CHOLESTASIS; LIPID METABOLISM; LIVER FIBROSIS; LIVER INJURY; MOUSE; MOUSE STRAIN; MUTATION; NONHUMAN; PATHOLOGY; PRIORITY JOURNAL; REVIEW; STEROIDOGENESIS;

ANIMALIA; EUKARYOTA; STAPHYLOCOCCUS PHAGE 3A;

EID: 0037255188     PISSN: 00916765     EISSN: None     Source Type: Journal    
DOI: 10.1289/txg.5849     Document Type: Review

References (37)

1. Barclay TB, Peters JM, Sewer MB, Ferrari L, Gonzalez FJ, Morgan ET. 1999. Modulation of cytochrome P-450 gene expression in endotoxemix mice is tissue specific and peroxisome proliferator-activated receptor-dependent. J Pharmacol Exp Ther 290:1250-1257.
2. Bellingham RM, Gibbs AH, De Matteis F, Lian LY, Roberts GC. 1995. Determination of the structure of an N-substituted protoporphyrin isolated from the livers of griseofulvin-fed mice. Biochem J 307:505-512.
3. Bissell MD, Gores GJ, Laskin DL, Hoofnagle JH. 2001. Drug-induced liver injury:mechanisms and test systems. Hepatology 33:1009-1013.
4. Bloomer J, Bruzzone C, Zhu L, Scarlett Y, Magness S, Brenner D. 1998. Molecular defects in ferrochelatase in patients with protoporphyria requiring liver transplantation. J Clin Invest 102:107-114.
5. Cadrin M, Hovington N, McFarlane-Anderson N. 2000. Early perturbations in keratin and actin gene expression and fibrillar organisation in griseofulvin-fed mouse liver. J Hepatol 33:199-207.
6. Camus-Random A-M, Raffalli F, Bereziat J-C, McGregor D, Konstandi M, Lang MA. 1996. Liver injury and expression of cytochromes P450: evidence that regulation of CYP2A5 is different from that of other major xenobiotic metabolizing CYP enzymes. Toxicol Appl Pharm 138:140-148.
7. Classon BJ. 2001. Ly-6 ligands remain elusive. Trends Immunol 22:126.
8. Cox TM, Alexander GJM, Sarkany RPE. 1998. Protoporphyria. Semin Liver Dis 18:85-93.
9. De Matteis F, Rimington C. 1963. Disturbance of porphyrin metabolism caused by griseofulvin in mice. Br J Dermatol 75:91-104.
10. De Matteis F, Donnelly AJ, Runge WJ. 1966. The effect of prolonged administration of griseofulvin in mice with reference to sex differences. Cancer Res 26:721-726.
11. Denk H, Gschnait F, Wolff K. 1975. Hepatocellular hyalin (Mallory bodies) in long term griseofulvin-treated mice: a new experimental model for the study of hyalin formation. Lab Invest 32:773-777.
12. Eisen MB, Spellman PT, Brown PO, Botstein D. 1998. Cluster analysis and display of genome-wide expression patterns. Proc Natl Acad Sci U S A 95:14863-14868.
13. Epstein LF, Bass MM, Iwahara S-I. Wilton DC. 1994. Immunological identity of rat liver cytosolic heme-binding protein with purified and recombinant liver fatty acid binding protein by Western blots of two-dimensional gels. Biochem biophys Res Commun 204:163-168.
14. Friedman SL. 1993. Seminars in medicine of the Beth Israel Hospital, Boston. The cellular basis of hepatic fibrosis. Mechanisms and treatment strategies. N Engl J Med 238:1825-1835.
15. Gant TW. 2002. Classifying toxicity and pathology by gene-expression profile - taking a lead from studies in neoplasia. Trends Pharmacol Sci 23:388-393.
16. Grandchamp B, Deybach JC, Grelier M, deVerneuil H, Nordmann Y. 1980. Studies of porphyrin synthesis in fibroblasts of patients with congenital erythropoietic poryphyria and one patient with homozygous coproporphyria. Biochem Biophys Acta 629:577.
17. Hamadeh HK, Bushel PR, Jayadev S, DiSorbo O, Bennett L, Tennant R, et al. 2002a. Prediction of compound signature using high density gene expression profiling. Toxicol Sci 67:232-240.
18. Hamadeh HK, Bushel PR, Jayadev S, Martin K, DiSorbo O, Sieber S, et al. 2002b. Gene expression analysis reveals chemical-specific profiles. Toxicol Sci 67:219-231.
19. Hamadeh HK, Knight BL, Haugen AC, Sieber S, Amin RP, Bushel PR, et al. 2002c. Mathapyrilene toxicity: anchorage of pathologic observation to gene expression alterations. Toxicol Pathol 30:470-482.
20. Harada T, Enomoto A, Boorman GA, Maronpot RR. 1999. Liver and gallbladder. In: Pathology of the Mouse (Maronpot RR, Boorman GA, Gaul BW, eds). Vienna:Cache River Press, 119-183.
21. Iyer V, Eisen MB, Ross DT, Schuler G, Moore T, Lee JC, et al. 1999. The transcriptional program in the reponse of human fibroblasts to serum. Science 283:83-87.
22. Kappas A, Sassa S, Galbraith RA, Nordmann Y. 1995. The porphyrias. In: the Metabolic and Molecular Basis of Inherited Disease (Scriver CR, Benaudet AL, Sly WS, Valle D, eds). New York:McGraw-Hill, 2103-2159.
23. Knasmuller S, Parzefall W, Helma C, Kassie F, Ecker S, Schulte-Herman R. 1997. Toxic effects of griseofulvin: disease models, mechanisms and risk assessment. CRC Crit Rev Toxicol 27:495-537.
24. Komatsu K, Kobune-Fujiwara Y, Andoh a, Ishiguro s, Hunai H, Suzuki N, et al. 2000. Increased expression of S100A6 at the invading fronts of the primary lesion and liver metastasis in patients with colorectal adenocarcinoma. Br J Cancer 83:769-774.
25. Ku NO, Gish R, Wright TL, Omary MB. 2001. Keratin 8 mutations in patients with cryptogenic liver disease. N Engl J Med 344:1580-1587.
26. Lee WM. 1995. Nuclear orphan receptors control choleterol catabolism. Cell 97:539-542.
27. Salonpaa P, Krause K, Pelkonen O, Raunio H. 1995. UP-regulation of CYP2A5 expression by porphyrinogenic agents in mouse liver. Nauny-Schmiedebergs Arch Pharmacol 351:446-452.
28. Shackelford C, Long G, Wolf J, Okerberg C, Herbert R. 2002. Qualitative and quantitative analysis of non-neoplatic lesions in toxicology studies. Toxicol Pathol 30:470-482.
29. Sinal CJ, Tohkin M, Miyata M, Ward JM, Lambert G, Gonzalez FJ. 2000. Targeted disruption of the nuclear receptor FXR/BAR impairs bile acid and lipid homeostasis. Cell 102:731-744.
30. Thomas RS, Rank DR, Penn SG, Zastrow GM, Hayes KR, Pande K, et al. 2001. Identification of toxicologically prdictive gene sets using cDNA microarrays. Mol Pharmacol 60:1189-1194.
31. Tilg H, Diehl AM. 2000. Cytokines in alcoholoic and nonalcoholic steatohepatitis. N Engl J Med 343:1467-1476.
32. Turton NJ, Judah DJ, Riley J, Davies R, Lipson D, Styles JA, et al. 2001. Gene expression and amplification in breast carcinoma cells with intrinsic and acquired doxorubicin resistance. Oncogene 20:1300-1306.
33. Tutois s, Montaguitelli X, Da Silva V, Jouault H, Rouyer-Fessard P, Leroy-Viard K, et al. 1991. Erythropoietic protoporphyria in the house mouse. J Clin Invest 88:1730-1736.
34. Vincent SH, Smith AG, Muller-Eberhard U. 1989. Modulation of hepatic heme-binding Z protein in mice by the porphyrogenic carcinogens griseofulvin and hexachlorobenzene. Cancer Lett 45:109-114.
35. Waring JF, Ciurlionis R, Jolly RA, Heindel M, Ulrich RG. 2001. Microarray analysis of hepatotoxins in vitro reveals a correlation between gene expresion profiles and mechanisms of toxicity. Toxicol Lett 120:359-368.
36. Wastl UM, Rossmanith W, Lang MA, Camus-Randon AM, Grasl-Kraupp B, Bursch W, et al. 1998. Expression of cytochrome P450 2A5 in preneoplastic and neoplastic mouse liver lesions. Mol Carcinogen 22:229-234.
37. Weston Hurst E, Paget GE. 1963. Protoporphyrin, cirrhosis and hepatoma in the livers of mice given griseofulvin. Br J Dermatol 75:105-112.